Chuangsheng Group announced that its anti-sclerostin monoclonal antibody TST002 was approved for clinical use in China

Suzhou, September 27, 2021/PRNewswire/ - Chuangsheng Group, a clinical-stage biopharmaceutical company with the ability to integrate the entire process of biopharmaceutical discovery, R&D, process development and production, announced today that it is targeting severe osteoporosis The anti-sclerostin monoclonal antibody TST002 was officially approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) on September 22.

At present, more than 100 million people in China suffer from osteoporosis of varying degrees, and 4 million of them suffer from severe osteoporosis.

TST002 (Blosozumab) is a humanized anti-sclerostin monoclonal antibody drug candidate for severe osteoporosis.

TST002 (Blosozumab) is the earliest research and development by Eli Lilly and has completed Phase II clinical studies in the United States and Japan

"As the population ageing trend intensifies, osteoporosis is bringing a heavier disease burden to the Chinese medical system

About Chuangsheng Group

Chuangsheng Group is a clinical stage biopharmaceutical company with comprehensive capabilities in biopharmaceutical discovery, research and development, process development and production